(MedPage Today) — The FDA approved zanidatamab (Ziihera) plus tislelizumab (Tevimbra) and chemotherapy as first-line treatment for unresectable/metastatic HER2-positive gastroesophageal cancer.
The approval stipulates use in adults with unresectable…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
